Joakim Alfredsson
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Aims Previous studies on disparities in healthcare and outcomes have shown conflicting results. The aim of this study was to assess differences in baseline characteristics, management, and outcomes in myocardial infarction (MI) patients, by country of birth. Methods and results In total, 194 259 MI patients (64% male, 15% foreign-born) from the nationwide SWEDEHEART (The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry were included and compared by geographic region of birth. The primary outcome was 1-year major adverse cardiovascular events (MACEs) including all-cause death, MI, and stroke. Secondary outcomes were long-term MACE (up to 12 years), the individual components of MACE, 30-day mortality, management, and risk factors. Logistic regression, Cox proportional hazard models, and propensity score match (PSM), accounting for baseline differences, were used. Foreign-born patients were younger, often male, and had a higher cardiovascular (CV) risk factor burden, including smoking, diabetes, and hypertension. In PSM analyses, Asia-born patients had higher likelihood of revascularization [odds ratio 1.16, 95% confidence interval (CI) 1.04–1.30], statins and beta-blocker prescription at discharge, and a 34% lower risk of 30-day mortality. Furthermore, no statistically significant differences were found in primary outcomes except for Asia-born patients having lower risk of 1-year MACE [hazard ratio (HR) 0.85, 95% CI 0.73–0.98], driven by lower mortality (HR 0.72, 95% CI 0.57–0.91). The results persisted over the long-term follow-up. Conclusion This study shows that in a system with universal healthcare coverage in which acute and secondary preventive treatments do not differ by country of birth, foreign-born patients, despite higher CV risk factor burden, will do at least as well as native-born patients.
Year:
2024
Background The use of inotropic agents in treating cardiogenic shock (CS) remains controversial. We aimed to investigate the effect of treatment with inotropes on 30-day mortality in patients with CS from the SWEDEHEART registry (The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies). Methods We used data from the national SWEDEHEART registry on all patients diagnosed with CS in Sweden between 2000 and 2022. The primary endpoint was 30-day all-cause mortality. We used multilevel Cox proportional-hazards regression with instrumental variable and inverse probability weighting propensity score to adjust for known and unknown confounders. The treatment-preference instrument was the quintile of preference for using inotropes at the treating hospital. Results In total, 16,214 patients (60.5% men and 39.5% women) were included; 23.5% had diabetes, 10.2% had a previous myocardial infarction (MI), and 13.8% had previous heart failure (HF). The median age was 70 years (interquartile range; 19), and 66.4% were >70. Acute coronary syndrome (ACS) was the cause of CS in 82.9% of patients. Inotropic agents were used in 43.8% of patients, while 56.2% did not receive inotropic agents. There were 7,875 (48.1%) deaths. On average, patients treated with inotropes were two years younger and more likely to have ACS. Patients not treated with inotropes were more likely to have previous MI and previous PCI but less likely to undergo PCI. The number of patients with CS decreased by 12% per year (P trend <0.001). There was a considerable variation between hospitals in the preference for using inotropes ranging from 25 to 78% (P<0.001). Inotropes increased by 5% per year (P trend <0.001). The unadjusted mortality in CS increased by 2% per calendar year (P trend <0.001). The risk of death was higher in patients treated with inotropes [adjusted hazard ratio (HR adj ) 1.72; 95% confidence interval (CI) 1.26-2.35; P=0.001]. There was a quantitative interaction between inotrope treatment and age and diagnosis (P interaction < 0.001 and P interaction = 0.018, respectively). Conclusions In this observational study, using inotropes was associated with a higher mortality risk in patients with CS. The increased risk of death was more pronounced in patients younger than 70. The number of patients with CS is decreased, while the use of inotropes and mortality increased in Sweden.
Year:
2024
Collaborators (6)
Elmir Omerovic
Chair Professor of Cardiology
University of Gothenburg
Ole Frobert
Professor
Aarhus University
Tomas Jernberg
Professor
Karolinska Institutet
David Erlinge
Lund University
Björn Redfors
University of Gothenburg
Oskar Angerås
Karolinska University Hospital
Make your next move.
Prepare your application
Review drafts before you send them.